Metastatic uveal melanoma managed with best supportive care

References

• Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651–4659.
   PubMed Web of Science ®Google Scholar
• Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005;123(12):1639–1643.
   PubMed Web of Science ®Google Scholar
• Eskelin S, Pyrhönen S, Hahka-Kemppinen M, et al. A prognostic model and staging for metastatic uveal melanoma. Cancer. 2003;97(2):465–475.
   PubMed Web of Science ®Google Scholar
• Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29(6):561–568.
   PubMed Web of Science ®Google Scholar
• Khoja L, Atenafu EG, Suciu S, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30(8):1370–1380.
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Piperno-Neumann S, Kapiteijn E, et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT). J Clin Oncol. 2018;36(12):1232–1239.
   PubMed Web of Science ®Google Scholar
• Zimmer L, Vaubel J, Mohr P, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma . PLoS One. 2015;10(3):e0118564.
   PubMed Web of Science ®Google Scholar
• Augsburger JJ, Corrêa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol. 2009;148(1):119–127.
   PubMed Web of Science ®Google Scholar
• Jochems A, van der Kooij MK, Fiocco M, et al. Metastatic uveal melanoma: treatment strategies and survival-results from the Dutch melanoma treatment registry. Cancers (Basel). 2019;11(7):1007.
   Web of Science ®Google Scholar
• Kivelä TT, Piperno-Neumann S, Desjardins L, et al. Validation of a prognostic staging for metastatic uveal melanoma: a collaborative study of the European Ophthalmic Oncology Group. Am J Ophthalmol. 2016;168:217–226.
   PubMed Web of Science ®Google Scholar
• Cherny NI, Catane R, Kosmidis P, ESMO Taskforce on Supportive and Palliative Care. ESMO takes a stand on supportive and palliative care. Ann Oncol. 2003;14(9):1335–1337.
   PubMed Web of Science ®Google Scholar
• Lee RT, Ramchandran K, Sanft T, et al. Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer†. Ann Oncol. 2015;26(9):1838–1845.
   PubMed Web of Science ®Google Scholar
• Moy CS, Albert DM, Diener-West M, et al.; Collaborative Ocular Melanoma Study Group, prepared by COMS Mortality Coding Committee. Cause-specific mortality coding: methods in the Collaborative Ocular Melanoma Study. COMS report. Control Clin Trials. 2001;22(3):248–262. no.
   PubMedGoogle Scholar
• Kivelä TT, Simpson ER, Grossniklaus HE, et al. Uveal melanoma. In: Amin MB, Edge S, Greene F, et al. editors. AJCC cancer staging manual. 8th ed. Chicago, USA: Springer International Publishing; 2017. p. 813–826.
   Google Scholar
• Kujala E, Damato B, Coupland SE, et al. Staging of ciliary body and choroidal melanomas based on anatomic extent. J Cin Oncol. 2013;31(22):2825–2831.
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–655.
   PubMed Web of Science ®Google Scholar
• Eskelin S, PyrhöNen S, Summanen P, et al. Screening for metastatic malignant melanoma of the uvea revisited. Cancer. 1999;85(5):1151–1159.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–216.
   PubMed Web of Science ®Google Scholar
• Grambsch PM, Therneau TM, Fleming TR. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics. 1995;51(4):1469–1482.
   PubMed Web of Science ®Google Scholar
• Lane AM, Kim IK, Gragoudas ES. Survival rates in patients after treatment for metastasis from uveal melanoma. JAMA Ophthalmol. 2018;136(9):981–986.
   PubMed Web of Science ®Google Scholar
• Gomez D, Wetherill C, Cheong J, et al. The Liverpool uveal melanoma liver metastases pathway: outcome following liver resection. J Surg Oncol. 2014;109(6):542–547.
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98(3):383–389.
   PubMed Web of Science ®Google Scholar
• Pons F, Plana M, Caminal JM, et al. Metastatic uveal melanoma: Is there a role for conventional chemotherapy? - A single center study based on 58 patients. Melanoma Res. 2011;21(3):217–222.
   PubMed Web of Science ®Google Scholar
• Nicholas MN, Khoja L, Atenafu EG, et al. Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience. Melanoma Res. 2018;28(6):571–577.
   PubMed Web of Science ®Google Scholar
• Xu LT, Funchain PF, Bena JF, et al. Uveal melanoma metastatic to the liver: treatment trends and outcomes. Ocul Oncol Pathol. 2019;5(5):323–332.
   PubMed Web of Science ®Google Scholar
• Kivelä T, Suciu S, Hansson J, et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer. 2003;39(8):1115–1120.
   PubMed Web of Science ®Google Scholar
• Pyrhönen S, Hahka-Kemppinen M, Muhonen T, et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer. 2002;95(11):2366–2372.
   PubMed Web of Science ®Google Scholar
• Vihinen PP, Hernberg M, Vuoristo MS, et al. A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma. Melanoma Res. 2010;20(4):318–325.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics - guidance for industry 2018. [cited 2020 July 6]. Available from: https://www.fda.gov/media/71195/download
   Google Scholar
• European Medicines Agency. Guideline on the evaluation of anticancer medicinal products in man 2005. [cited 2020 July 6]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-anticancer-medicinal-products-man-revision-3_en.pdf
   Google Scholar
• Rodrigues M, Mobuchon L, Houy A, et al. Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors. Nat Commun. 2018;9(1):1866.
   PubMedGoogle Scholar
• Rodrigues M, Mobuchon L, Houy A, et al. Evolutionary routes in metastatic uveal melanomas depend on MBD4 alterations. Clin Cancer Res. 2019;25(18):5513–5524.
   PubMed Web of Science ®Google Scholar
• Repo P, Jäntti J, Järvinen R-S, et al. Germline loss-of-function variants in MBD4 are rare in Finnish patients with uveal melanoma. Pigment Cell Melanoma Res. 2020;33(5):756–762.
   PubMed Web of Science ®Google Scholar